SlideShare une entreprise Scribd logo
1  sur  42
The Transfusion Trigger:
  When Should You
    Give Red Cells?

    Harriet W. Hopf, MD
    Professor of Anesthesiology
         University of Utah
Goals
   To understand
     the effect of anemia on oxygen transport
     mechanisms that compensate for anemia

     the risks of transfusion

     the concept of a transfusion trigger
Objective
   Participants will be able persuasively to
    defend their decision to transfuse / not to
    transfuse red cells
Why Transfuse Red Cells?
Why Transfuse Red Cells?
   To maintain O2 delivery to organs
   To prevent inadequate O2 consumption
How Do We Measure Need?
   Ideal
       Tissue oxygen
   Good-- but not practical
       O2ER (VO2/DO2)
           Madjdpour and Spahn. BJA 2005; 95:33-42
   Real
       Hemoglobin
       Hemodynamics
Physiologic Effects of Anemia
   Why is there a wide range of “normal” and
    “acceptable” hemoglobin?
Physiologic Effects of Anemia
   Compensate by increased cardiac output
       CO = HR X SV
   HR increases 4 bpm / g Hb
   SV increases as well
       Increased contractility (active)
       Decreased SVR (passive)
       Increased venous return (passive)
                 Weiskopf et al. Transfusion 2003; 43: 235-40
Physiologic Effects of Anemia
   Under anesthesia, no HR increase
   Increased CO is from increased SV




              Majdpour and Spahn. BJA 2005; 95:33-42.
Fick’s Principle
Fick’s Principle
   CO = VO2 / AVDO2
       AVDO2 = CaO2-CvO2
       CO2 = SO2(HbX1.34) + PO2(0.003)
           mL O2 / dL blood
Does Dissolved Oxygen Matter?
Hemoglobin bound oxygen
  Hb (g/dL)
              14       10       7          3
PaO2 (mmHg)
   CaO2        18.76    13.40       9.38       4.02

    100
               18.76    13.40       9.38       4.02
    500
               18.76    13.40       9.38       4.02
   2000
Dissolved Oxygen
  Hb (g/dL)
              14          10          7          3
PaO2 (mmHg)
   CaO2            0.30        0.30       0.30       0.30

    100
                   1.50        1.50       1.50       1.50
    500
                   6.00        6.00       6.00       6.00
   2000
Putting it all together
  Hb (g/dL)
              14       10       7          3
PaO2 (mmHg)
   CaO2        18.76    13.40       9.38        4.02
                0.30     0.30       0.30        0.30
    100        19.06    13.70       9.68        4.32
               18.76    13.40    9.38           4.02
                1.50     1.50    1.50           1.50
    500        20.26    14.90   10.88           5.52
               18.76    13.40    9.38           4.02
                6.00     6.00    6.00           6.00
   2000        24.76    19.40   15.38          10.02
Does Dissolved Oxygen Matter?
What if you can’t transfuse?
What if you can’t transfuse?
   Administer 100% oxygen
       Equivalent to 1-1.5 g/dL Hb
            1 g Hb fully saturated = 1.34 mL O2
            PaO2 500 mm Hg = 1.5 mL O2
            PaO2 300 mm Hg = 0.9 mL O2




     Weiskopf et al. Anesthesiology, 96(4), 871-7, 2002.
Dissolved Oxygen Matters!!!
  Hb (g/dL)
              14       10       7          3
PaO2 (mmHg)
   CaO2        18.76    13.40       9.38        4.02
                0.30     0.30       0.30        0.30
    100        19.06    13.70       9.68        4.32
               18.76    13.40    9.38           4.02
                1.50     1.50    1.50           1.50
    500        20.26    14.90   10.88           5.52
               18.76    13.40    9.38           4.02
                6.00     6.00    6.00           6.00
   2000        24.76    19.40   15.38          10.02
What Happens to AVDO2?
   Normal AVDO2 using Fick’s Equation
   Hb 14 g/dL
       CO 50 dL / min (5 Lpm)
       VO2 250 mL O2 / min
   AVDO2 = 250/50 = 5
       CaO2 19 mL O2/dL blood
       CvO2 14 mL O2/dL blood
       p50 CvO2 = 7
What if AVDO2 Doesn’t Change?
  Hb (g/dL)
              14       10
PaO2 (mmHg)
   CaO2        18.76    13.40          13.7 - 5 = 8.7
                0.30     0.30
    100        19.06    13.70   Close enough to 7!!!
What Happens to AVDO2?
   Assume CO can increase
       Hb 7 g/dL
       CO 100 dL / min (10 Lpm)
       VO2 250 mL O2 / min
   AVDO2 = 250/100 = 2.5
What if AVDO2 Does Change?
  Hb (g/dL)
                 14           10          7
PaO2 (mmHg)
   CaO2               18.76      13.40        9.38
                       0.30       0.30        0.30
    100               19.06      13.70        9.68

          CvO2
                 14.06        8.70       4.68
 AVDO2 = 5
      CvO2
                 16.56        11.20      7.18
 AVDO2 = 2.5
What if you can’t transfuse?
   Maximize CaO2
       FiO2 1.0
       Hyperbaric oxygen (intermittent)
   Minimize VO2
       Intubate
       Paralyze
       Sedate
       Cool (?) to 35.5C
What if you can’t transfuse?
   Maximize CO
       Volume
           Goal is isovolemia
           Consider TEE guidance
           Don’t measure Hb!
       Don’t use dopamine
           Increased VO2 mostly cardiac
Dissolved Oxygen Matters!!!
  Hb (g/dL)
              14       10       7          3
PaO2 (mmHg)
   CaO2        18.76    13.40       9.38        4.02
                0.30     0.30       0.30        0.30
    100        19.06    13.70       9.68        4.32
               18.76    13.40    9.38           4.02
                1.50     1.50    1.50           1.50
    500        20.26    14.90   10.88           5.52
               18.76    13.40    9.38           4.02
                6.00     6.00    6.00           6.00
   2000        24.76    19.40   15.38          10.02
Risks of Transfusion
   Infection
       HIV         1: 500K-1500K
       HBV         1:30K-200K
       HCV         1: 2000K-3000K
       Bacterial   1:28K-43K
       Malaria     1:4000K
       vCJD        Recent reports

                      Majdpour and Spahn. BJA 2005; 95:33-42.
Risks of Transfusion
   Transfusion Reaction 1:13K
   Mistransfusion       1:14K-18K
   TRALI                1:5K-529K

   Expensive
   Limited supply

                     Majdpour and Spahn. BJA 2005; 95:33-42.
Risks of Transfusion
   Cancer recurrence
   Surgical site infection
   Mortality

   Role for leucoreduction?
   Old vs. new blood?
          Koch et al, NEJM 358:1229, 2008
          Weiskopf et al, Anesth. 104:911, 2006
                           Majdpour and Spahn. BJA 2005; 95:33-42.
Transfusion Guidelines
   Are there guidelines?
       ASA Guidelines, Anesth 105:198-208, 2006.
   Are they based on data?
       “strongly agree” transfuse < 6 g/dL
       “strongly agree” don’t transfuse >10g/dL
   How good are physicians at following them?
Joint Commission
          Patient Blood Management Performance Measures Project
             Transfusion Consent

             RBC Transfusion Indication

             Plasma Transfusion Indication

             Platelet Transfusion Indication

             Blood Administration Indication

             Preoperative Anemia Screen

             Preoperative Blood Type / Antibody Screen




http://www.jointcommission.org/patient_blood_management_performance_measures_project/
Transfusion Trigger
   Really a TARGET not a TRIGGER
   Healthy patient
       7 g / dL
   Cardiopulmonary disease
       10 g / dL (?8-9)
       Prevent tachycardia
What does this mean?
   Healthy patient, Hb 14 g/dL
   Assume 500 mL (1 unit) whole blood loss = 1
    g/dL Hb decrease
   Assume volume replaced
   EBL >3500 mL before consider transfusion
How low can you go?
   Unmedicated, healthy volunteers at rest
       Hb 5 g / dL
            No VO2-DO2 dependency
            Fatigued
            Mild cognitive impairment
                  Slightly slower and less accurate
                  Still in normal range
                  Reversed by RBC transfusion at Hb 7 g/dL
                  Reversed by 100% O2 via NRB
                  Weiskopf et al. Anesthesiology, 96(4), 871-7, 2002.
What about surgical patients?
   Anemia increases 30-day mortality, CV
    complications, and LOS
       Non-cardiac surgery
            Polycythemia similar effects
                 Wu et al. JAMA 297:2481, 2007 (98% men)

       Colorectal surgery
                 ~50% women but not analyzed separately
                 Leichtle et al, J Am Coll Surg 212:187, 20011

       Cardiac surgery
                 Koch et al, Crit Care Med 34:1608, 2008
How Should We Manage Anemia?
    Is anemia a marker for disease or inherently
     causative?
    Preoperative treatment:
        2 weeks oral iron (200 mg) reduces transfusion
             9.4 vs 27.4%, p<0.05
                  Okuyama et alSurg Today 35:36, 2005

        ESA reduces transfusion, increases DVT
             Laupacis and Fergusson, Transfus Med 8:309, 1998
How Should We Manage Anemia?
    Is anemia a marker for disease or inherently
     causative?
    Risk-adjusted, propensity-matched
        ≥4 U blood predicts increases:
             Mortality
             Infection
             LOS
                  Dunne et al, J Surg Res 102:237, 2002
Critical Care Transfusion RCT
   838 patients, Hb <9 g/dL, within 72 h of
    admit
     Trigger <7             Target 7-9
     Trigger <10            Target 10-12



               Hebert et al. NEJM, 1999; 340:409-17.
Critical Care Transfusion RCT
          Trigger
                    <7 g / dL   <10 g/dL   P value
30d Mortality

Overall               18.7        23.3      0.11
 APACHE II
                      8.7         16.1      0.03
   <21
Age <55 yr            5.7         13        0.02

CV Disease            20.5        22.9      0.69
Table 3. Unadjusted Rates of Outcomes and Adjusted Results of Cox Regression Predicting 30-Day
       Death and Death or Recurrent Myocardial Infarction Using Transfusion as a Time-Dependent
                                              Covariate.




                                                       HCT 25% best cut-off for transfusion
           Rao, S. V. et al. JAMA 2004;292:1555-1562



Copyright restrictions may apply.
Individualize
   Transfusion target (7 vs. 10 vs. 8…)
   Acute vs. chronic anemia
   Rate of bleeding
   Hemodynamics

   What about ADLs?
   Should target differ in men and women?
Summary
   Transfusions of RBC can be life-saving
   Also cause serious morbidity and mortality
   Individualize therapy
       Underlying disease
       Adequacy of compensatory responses
       Rate of bleeding
       Starting point

Contenu connexe

En vedette

IT for Nursing | Internet & WWW
IT for Nursing | Internet & WWWIT for Nursing | Internet & WWW
IT for Nursing | Internet & WWW
Sascha Funk
 
The Defense Industry In Western Central Pennsylvania
The Defense Industry In Western Central PennsylvaniaThe Defense Industry In Western Central Pennsylvania
The Defense Industry In Western Central Pennsylvania
Bob Shark
 
Designing a Customer Feedback Program to Measure and Improve User Satisfaction
Designing a Customer Feedback Program to Measure and Improve User SatisfactionDesigning a Customer Feedback Program to Measure and Improve User Satisfaction
Designing a Customer Feedback Program to Measure and Improve User Satisfaction
UserZoom
 
Bgs120 debopriyo roy
Bgs120 debopriyo royBgs120 debopriyo roy
Bgs120 debopriyo roy
Debopriyo Roy
 
Big Data and the growing relevance of NoSQL
Big Data and the growing relevance of NoSQLBig Data and the growing relevance of NoSQL
Big Data and the growing relevance of NoSQL
Abhijit Sharma
 
IT for Nurisng - Web 2.0
IT for Nurisng - Web 2.0IT for Nurisng - Web 2.0
IT for Nurisng - Web 2.0
Sascha Funk
 

En vedette (20)

Connexions Roy 2013
Connexions Roy 2013Connexions Roy 2013
Connexions Roy 2013
 
Ametid
AmetidAmetid
Ametid
 
Referaat 31 05 2011
Referaat 31 05 2011Referaat 31 05 2011
Referaat 31 05 2011
 
IT for Nursing | Internet & WWW
IT for Nursing | Internet & WWWIT for Nursing | Internet & WWW
IT for Nursing | Internet & WWW
 
Digital
DigitalDigital
Digital
 
RKB – A Semantic Knowledge Base For RNA (RNA ontology consortium meeting)
RKB – A Semantic Knowledge Base For RNA (RNA ontology consortium meeting)RKB – A Semantic Knowledge Base For RNA (RNA ontology consortium meeting)
RKB – A Semantic Knowledge Base For RNA (RNA ontology consortium meeting)
 
Stripgenerator
StripgeneratorStripgenerator
Stripgenerator
 
The Defense Industry In Western Central Pennsylvania
The Defense Industry In Western Central PennsylvaniaThe Defense Industry In Western Central Pennsylvania
The Defense Industry In Western Central Pennsylvania
 
Cassass presentation WLF2 Rome
Cassass presentation WLF2 RomeCassass presentation WLF2 Rome
Cassass presentation WLF2 Rome
 
The Globalized Patient
The Globalized PatientThe Globalized Patient
The Globalized Patient
 
Designing a Customer Feedback Program to Measure and Improve User Satisfaction
Designing a Customer Feedback Program to Measure and Improve User SatisfactionDesigning a Customer Feedback Program to Measure and Improve User Satisfaction
Designing a Customer Feedback Program to Measure and Improve User Satisfaction
 
Bgs120 debopriyo roy
Bgs120 debopriyo royBgs120 debopriyo roy
Bgs120 debopriyo roy
 
Cima Samples
Cima SamplesCima Samples
Cima Samples
 
1ºdt tema 1 t fundamentales en el plano1 v.7
1ºdt tema 1 t fundamentales en el plano1 v.71ºdt tema 1 t fundamentales en el plano1 v.7
1ºdt tema 1 t fundamentales en el plano1 v.7
 
Workplace sprituality
Workplace spritualityWorkplace sprituality
Workplace sprituality
 
Big Data and the growing relevance of NoSQL
Big Data and the growing relevance of NoSQLBig Data and the growing relevance of NoSQL
Big Data and the growing relevance of NoSQL
 
SecurVoice 2010
SecurVoice 2010SecurVoice 2010
SecurVoice 2010
 
Social Media and Fundraisng - are you prepared?
Social Media and Fundraisng - are you prepared? Social Media and Fundraisng - are you prepared?
Social Media and Fundraisng - are you prepared?
 
CloudCoffee
CloudCoffeeCloudCoffee
CloudCoffee
 
IT for Nurisng - Web 2.0
IT for Nurisng - Web 2.0IT for Nurisng - Web 2.0
IT for Nurisng - Web 2.0
 

Similaire à Hopf anemia09

Nguyen huu hoang ta
Nguyen huu hoang taNguyen huu hoang ta
Nguyen huu hoang ta
Duy Quang
 
Arterial Blood Gas Analysis
 Arterial Blood Gas Analysis Arterial Blood Gas Analysis
Arterial Blood Gas Analysis
intentdoc
 
Presentation 2006 Rcsw Acid Base Analysis
Presentation 2006 Rcsw Acid Base AnalysisPresentation 2006 Rcsw Acid Base Analysis
Presentation 2006 Rcsw Acid Base Analysis
Anjul Dayal
 

Similaire à Hopf anemia09 (20)

Nguyen huu hoang ta
Nguyen huu hoang taNguyen huu hoang ta
Nguyen huu hoang ta
 
the po
the pothe po
the po
 
Arterial blood gas analysis in respiratory disorders
Arterial blood gas analysis in respiratory disordersArterial blood gas analysis in respiratory disorders
Arterial blood gas analysis in respiratory disorders
 
Hemodynamic Puzzle
Hemodynamic PuzzleHemodynamic Puzzle
Hemodynamic Puzzle
 
Oxygen delivery and consumption in critical care
Oxygen delivery and consumption in critical care Oxygen delivery and consumption in critical care
Oxygen delivery and consumption in critical care
 
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
 
Arterial blood gas analysis assesment of oxygenation ventilation and acid base
Arterial blood gas analysis assesment of oxygenation ventilation and acid baseArterial blood gas analysis assesment of oxygenation ventilation and acid base
Arterial blood gas analysis assesment of oxygenation ventilation and acid base
 
Abg interpretation
Abg interpretationAbg interpretation
Abg interpretation
 
Arterial Blood Gas Analysis
 Arterial Blood Gas Analysis Arterial Blood Gas Analysis
Arterial Blood Gas Analysis
 
Penatalaksanaan gagal nafas pada pasien morbid obesitas dengan penyulit ppok,...
Penatalaksanaan gagal nafas pada pasien morbid obesitas dengan penyulit ppok,...Penatalaksanaan gagal nafas pada pasien morbid obesitas dengan penyulit ppok,...
Penatalaksanaan gagal nafas pada pasien morbid obesitas dengan penyulit ppok,...
 
Ltot norge2011
Ltot norge2011Ltot norge2011
Ltot norge2011
 
ABG - Interpretation
ABG - InterpretationABG - Interpretation
ABG - Interpretation
 
Presentation 2006 Rcsw Acid Base Analysis
Presentation 2006 Rcsw Acid Base AnalysisPresentation 2006 Rcsw Acid Base Analysis
Presentation 2006 Rcsw Acid Base Analysis
 
Acid Base Analysis
Acid Base AnalysisAcid Base Analysis
Acid Base Analysis
 
CKD Epidemiology 2014
CKD Epidemiology 2014CKD Epidemiology 2014
CKD Epidemiology 2014
 
Right atrial pressure as back-pressure for venous return
Right atrial pressure as back-pressure for venous returnRight atrial pressure as back-pressure for venous return
Right atrial pressure as back-pressure for venous return
 
Arterial blood gas presentation in ICU/OT
Arterial blood gas presentation in ICU/OTArterial blood gas presentation in ICU/OT
Arterial blood gas presentation in ICU/OT
 
ABG Analysis
ABG Analysis ABG Analysis
ABG Analysis
 
Eric Hoste - aki - IFAD 2012
Eric Hoste - aki - IFAD 2012Eric Hoste - aki - IFAD 2012
Eric Hoste - aki - IFAD 2012
 
DNB OSCE ON ABG
DNB OSCE ON ABGDNB OSCE ON ABG
DNB OSCE ON ABG
 

Plus de Harriet Hopf

Plus de Harriet Hopf (8)

Safe and Sustainable: Balancing Infection Control and Environmental Health (U...
Safe and Sustainable: Balancing Infection Control and Environmental Health (U...Safe and Sustainable: Balancing Infection Control and Environmental Health (U...
Safe and Sustainable: Balancing Infection Control and Environmental Health (U...
 
Infection Control Considerations for COVID-19: Lessons Learned
Infection Control Considerations for COVID-19: Lessons LearnedInfection Control Considerations for COVID-19: Lessons Learned
Infection Control Considerations for COVID-19: Lessons Learned
 
Hopf wia elevator pitch 2021
Hopf wia elevator pitch 2021Hopf wia elevator pitch 2021
Hopf wia elevator pitch 2021
 
Tell Less, Know More: Elevator Pitches and Presenting to Executive Leaders
Tell Less, Know More: Elevator Pitches and Presenting to Executive LeadersTell Less, Know More: Elevator Pitches and Presenting to Executive Leaders
Tell Less, Know More: Elevator Pitches and Presenting to Executive Leaders
 
Giving Constructive Feedback to GME Trainees
Giving Constructive Feedback to GME TraineesGiving Constructive Feedback to GME Trainees
Giving Constructive Feedback to GME Trainees
 
Hopf Gillespie lecture ANZCA 2019
Hopf Gillespie lecture ANZCA 2019 Hopf Gillespie lecture ANZCA 2019
Hopf Gillespie lecture ANZCA 2019
 
U of u anesth new poster template 19
U of u anesth new poster template 19U of u anesth new poster template 19
U of u anesth new poster template 19
 
Creating an effective talk
Creating an effective talkCreating an effective talk
Creating an effective talk
 

Dernier

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdf
SanaAli374401
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 

Dernier (20)

Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdf
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 

Hopf anemia09

  • 1. The Transfusion Trigger: When Should You Give Red Cells? Harriet W. Hopf, MD Professor of Anesthesiology University of Utah
  • 2. Goals  To understand  the effect of anemia on oxygen transport  mechanisms that compensate for anemia  the risks of transfusion  the concept of a transfusion trigger
  • 3. Objective  Participants will be able persuasively to defend their decision to transfuse / not to transfuse red cells
  • 5. Why Transfuse Red Cells?  To maintain O2 delivery to organs  To prevent inadequate O2 consumption
  • 6. How Do We Measure Need?  Ideal  Tissue oxygen  Good-- but not practical  O2ER (VO2/DO2)  Madjdpour and Spahn. BJA 2005; 95:33-42  Real  Hemoglobin  Hemodynamics
  • 7. Physiologic Effects of Anemia  Why is there a wide range of “normal” and “acceptable” hemoglobin?
  • 8. Physiologic Effects of Anemia  Compensate by increased cardiac output  CO = HR X SV  HR increases 4 bpm / g Hb  SV increases as well  Increased contractility (active)  Decreased SVR (passive)  Increased venous return (passive) Weiskopf et al. Transfusion 2003; 43: 235-40
  • 9. Physiologic Effects of Anemia  Under anesthesia, no HR increase  Increased CO is from increased SV Majdpour and Spahn. BJA 2005; 95:33-42.
  • 11. Fick’s Principle  CO = VO2 / AVDO2  AVDO2 = CaO2-CvO2  CO2 = SO2(HbX1.34) + PO2(0.003)  mL O2 / dL blood
  • 13. Hemoglobin bound oxygen Hb (g/dL) 14 10 7 3 PaO2 (mmHg) CaO2 18.76 13.40 9.38 4.02 100 18.76 13.40 9.38 4.02 500 18.76 13.40 9.38 4.02 2000
  • 14. Dissolved Oxygen Hb (g/dL) 14 10 7 3 PaO2 (mmHg) CaO2 0.30 0.30 0.30 0.30 100 1.50 1.50 1.50 1.50 500 6.00 6.00 6.00 6.00 2000
  • 15. Putting it all together Hb (g/dL) 14 10 7 3 PaO2 (mmHg) CaO2 18.76 13.40 9.38 4.02 0.30 0.30 0.30 0.30 100 19.06 13.70 9.68 4.32 18.76 13.40 9.38 4.02 1.50 1.50 1.50 1.50 500 20.26 14.90 10.88 5.52 18.76 13.40 9.38 4.02 6.00 6.00 6.00 6.00 2000 24.76 19.40 15.38 10.02
  • 17. What if you can’t transfuse?
  • 18. What if you can’t transfuse?  Administer 100% oxygen  Equivalent to 1-1.5 g/dL Hb  1 g Hb fully saturated = 1.34 mL O2  PaO2 500 mm Hg = 1.5 mL O2  PaO2 300 mm Hg = 0.9 mL O2 Weiskopf et al. Anesthesiology, 96(4), 871-7, 2002.
  • 19. Dissolved Oxygen Matters!!! Hb (g/dL) 14 10 7 3 PaO2 (mmHg) CaO2 18.76 13.40 9.38 4.02 0.30 0.30 0.30 0.30 100 19.06 13.70 9.68 4.32 18.76 13.40 9.38 4.02 1.50 1.50 1.50 1.50 500 20.26 14.90 10.88 5.52 18.76 13.40 9.38 4.02 6.00 6.00 6.00 6.00 2000 24.76 19.40 15.38 10.02
  • 20. What Happens to AVDO2?  Normal AVDO2 using Fick’s Equation  Hb 14 g/dL  CO 50 dL / min (5 Lpm)  VO2 250 mL O2 / min  AVDO2 = 250/50 = 5  CaO2 19 mL O2/dL blood  CvO2 14 mL O2/dL blood  p50 CvO2 = 7
  • 21. What if AVDO2 Doesn’t Change? Hb (g/dL) 14 10 PaO2 (mmHg) CaO2 18.76 13.40 13.7 - 5 = 8.7 0.30 0.30 100 19.06 13.70 Close enough to 7!!!
  • 22. What Happens to AVDO2?  Assume CO can increase  Hb 7 g/dL  CO 100 dL / min (10 Lpm)  VO2 250 mL O2 / min  AVDO2 = 250/100 = 2.5
  • 23. What if AVDO2 Does Change? Hb (g/dL) 14 10 7 PaO2 (mmHg) CaO2 18.76 13.40 9.38 0.30 0.30 0.30 100 19.06 13.70 9.68 CvO2 14.06 8.70 4.68 AVDO2 = 5 CvO2 16.56 11.20 7.18 AVDO2 = 2.5
  • 24. What if you can’t transfuse?  Maximize CaO2  FiO2 1.0  Hyperbaric oxygen (intermittent)  Minimize VO2  Intubate  Paralyze  Sedate  Cool (?) to 35.5C
  • 25. What if you can’t transfuse?  Maximize CO  Volume  Goal is isovolemia  Consider TEE guidance  Don’t measure Hb!  Don’t use dopamine  Increased VO2 mostly cardiac
  • 26. Dissolved Oxygen Matters!!! Hb (g/dL) 14 10 7 3 PaO2 (mmHg) CaO2 18.76 13.40 9.38 4.02 0.30 0.30 0.30 0.30 100 19.06 13.70 9.68 4.32 18.76 13.40 9.38 4.02 1.50 1.50 1.50 1.50 500 20.26 14.90 10.88 5.52 18.76 13.40 9.38 4.02 6.00 6.00 6.00 6.00 2000 24.76 19.40 15.38 10.02
  • 27. Risks of Transfusion  Infection  HIV 1: 500K-1500K  HBV 1:30K-200K  HCV 1: 2000K-3000K  Bacterial 1:28K-43K  Malaria 1:4000K  vCJD Recent reports Majdpour and Spahn. BJA 2005; 95:33-42.
  • 28. Risks of Transfusion  Transfusion Reaction 1:13K  Mistransfusion 1:14K-18K  TRALI 1:5K-529K  Expensive  Limited supply Majdpour and Spahn. BJA 2005; 95:33-42.
  • 29. Risks of Transfusion  Cancer recurrence  Surgical site infection  Mortality  Role for leucoreduction?  Old vs. new blood?  Koch et al, NEJM 358:1229, 2008  Weiskopf et al, Anesth. 104:911, 2006 Majdpour and Spahn. BJA 2005; 95:33-42.
  • 30. Transfusion Guidelines  Are there guidelines?  ASA Guidelines, Anesth 105:198-208, 2006.  Are they based on data?  “strongly agree” transfuse < 6 g/dL  “strongly agree” don’t transfuse >10g/dL  How good are physicians at following them?
  • 31. Joint Commission  Patient Blood Management Performance Measures Project  Transfusion Consent  RBC Transfusion Indication  Plasma Transfusion Indication  Platelet Transfusion Indication  Blood Administration Indication  Preoperative Anemia Screen  Preoperative Blood Type / Antibody Screen http://www.jointcommission.org/patient_blood_management_performance_measures_project/
  • 32. Transfusion Trigger  Really a TARGET not a TRIGGER  Healthy patient  7 g / dL  Cardiopulmonary disease  10 g / dL (?8-9)  Prevent tachycardia
  • 33. What does this mean?  Healthy patient, Hb 14 g/dL  Assume 500 mL (1 unit) whole blood loss = 1 g/dL Hb decrease  Assume volume replaced  EBL >3500 mL before consider transfusion
  • 34. How low can you go?  Unmedicated, healthy volunteers at rest  Hb 5 g / dL  No VO2-DO2 dependency  Fatigued  Mild cognitive impairment  Slightly slower and less accurate  Still in normal range  Reversed by RBC transfusion at Hb 7 g/dL  Reversed by 100% O2 via NRB Weiskopf et al. Anesthesiology, 96(4), 871-7, 2002.
  • 35. What about surgical patients?  Anemia increases 30-day mortality, CV complications, and LOS  Non-cardiac surgery  Polycythemia similar effects  Wu et al. JAMA 297:2481, 2007 (98% men)  Colorectal surgery  ~50% women but not analyzed separately  Leichtle et al, J Am Coll Surg 212:187, 20011  Cardiac surgery  Koch et al, Crit Care Med 34:1608, 2008
  • 36. How Should We Manage Anemia?  Is anemia a marker for disease or inherently causative?  Preoperative treatment:  2 weeks oral iron (200 mg) reduces transfusion  9.4 vs 27.4%, p<0.05  Okuyama et alSurg Today 35:36, 2005  ESA reduces transfusion, increases DVT  Laupacis and Fergusson, Transfus Med 8:309, 1998
  • 37. How Should We Manage Anemia?  Is anemia a marker for disease or inherently causative?  Risk-adjusted, propensity-matched  ≥4 U blood predicts increases:  Mortality  Infection  LOS  Dunne et al, J Surg Res 102:237, 2002
  • 38. Critical Care Transfusion RCT  838 patients, Hb <9 g/dL, within 72 h of admit  Trigger <7 Target 7-9  Trigger <10 Target 10-12 Hebert et al. NEJM, 1999; 340:409-17.
  • 39. Critical Care Transfusion RCT Trigger <7 g / dL <10 g/dL P value 30d Mortality Overall 18.7 23.3 0.11 APACHE II 8.7 16.1 0.03 <21 Age <55 yr 5.7 13 0.02 CV Disease 20.5 22.9 0.69
  • 40. Table 3. Unadjusted Rates of Outcomes and Adjusted Results of Cox Regression Predicting 30-Day Death and Death or Recurrent Myocardial Infarction Using Transfusion as a Time-Dependent Covariate. HCT 25% best cut-off for transfusion Rao, S. V. et al. JAMA 2004;292:1555-1562 Copyright restrictions may apply.
  • 41. Individualize  Transfusion target (7 vs. 10 vs. 8…)  Acute vs. chronic anemia  Rate of bleeding  Hemodynamics  What about ADLs?  Should target differ in men and women?
  • 42. Summary  Transfusions of RBC can be life-saving  Also cause serious morbidity and mortality  Individualize therapy  Underlying disease  Adequacy of compensatory responses  Rate of bleeding  Starting point

Notes de l'éditeur

  1. 1.5 with 500 mmHg or 1.34 with 1 g Hb
  2. Table 3. Unadjusted Rates of Outcomes and Adjusted Results of Cox Regression Predicting 30-Day Death and Death or Recurrent Myocardial Infarction Using Transfusion as a Time-Dependent Covariate